| Generic name | Belinostat |
| Pronunciation | beh-LIH-noh-STAT |
| Brand name(s), other common name(s) | Beleodaq® |
| Drug type | Histone deacetylase inhibitor |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Belinostat is FDA approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Side effects needing medical attention
Side effects needing medical attention: nausea, fatigue, fever, anemia, and vomiting, constipation, diarrhea, shortness of breath, rash, peripheral edema (Leg swelling caused by the fluid in leg tissues), cough, low platelet count, itching, chills, increased blood lactate dehydrogenase, decreased appetite, headache, infusion site pain, hypokalemia, prolonged QT, abdominal pain, hypotension, phlebitis, dizziness. The most common serious adverse reactions were pneumonia, fever, infection, low red blood cell count, increased creatinine, low platelet count, and multi-organ failure.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.